Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor CAR T-cell (CAR-T), is a major second- or third-line treatment in refractory or early relapsed large B-cell lymphoma (LBCL), primary mediastinal large B-cell lymphoma (PMBL) and follicular lymphoma (FL) [1]. Although axi-cel induces high complete response rates in relapsed or refractory LBCL, PMBL, and FL, relapse remains the leading cause of treatment failure.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
